- Home
- MAN vs IBRX Comparison
MAN vs IBRX Comparison
Compare MAN & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAN
- IBRX
- Stock Information
- Founded
- MAN 1948
- IBRX 2014
- Country
- MAN United States
- IBRX United States
- Employees
- MAN N/A
- IBRX N/A
- Industry
- MAN Professional Services
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MAN Consumer Discretionary
- IBRX Health Care
- Exchange
- MAN Nasdaq
- IBRX Nasdaq
- Market Cap
- MAN 2.9B
- IBRX 2.4B
- IPO Year
- MAN 1988
- IBRX N/A
- Fundamental
- Price
- MAN $58.61
- IBRX $2.82
- Analyst Decision
- MAN Hold
- IBRX Buy
- Analyst Count
- MAN 6
- IBRX 2
- Target Price
- MAN $76.60
- IBRX $17.38
- AVG Volume (30 Days)
- MAN 578.5K
- IBRX 5.6M
- Earning Date
- MAN 01-28-2025
- IBRX 11-12-2024
- Dividend Yield
- MAN 5.24%
- IBRX N/A
- EPS Growth
- MAN N/A
- IBRX N/A
- EPS
- MAN 0.78
- IBRX N/A
- Revenue
- MAN $18,084,700,000.00
- IBRX $7,332,000.00
- Revenue This Year
- MAN N/A
- IBRX $2,572.99
- Revenue Next Year
- MAN $1.14
- IBRX $747.59
- P/E Ratio
- MAN $75.42
- IBRX N/A
- Revenue Growth
- MAN N/A
- IBRX 1218.71
- 52 Week Low
- MAN $58.74
- IBRX $2.82
- 52 Week High
- MAN $80.25
- IBRX $10.53
- Technical
- Relative Strength Index (RSI)
- MAN 34.03
- IBRX 29.17
- Support Level
- MAN $58.74
- IBRX $2.82
- Resistance Level
- MAN $61.21
- IBRX $3.18
- Average True Range (ATR)
- MAN 1.28
- IBRX 0.28
- MACD
- MAN -0.24
- IBRX -0.23
- Stochastic Oscillator
- MAN 5.26
- IBRX 1.25
About MAN ManpowerGroup
ManpowerGroup Inc. is engaged in providing workforce solutions and services. The company provides services that includes Recruitment and Assessment, Upskilling, Reskilling, Training and Development, Career Management, Outsourcing, and Workforce Consulting. The reportable segments of the company are Staffing and Interim, Outcome-Based Solutions and Consulting, Permanent Recruitment, and Others. The Staffing and Interim segment derives maximum of the company's revenue. The company derives maximum geographical revenue from Southern European region.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.